Drug Profile
SP 20201
Alternative Names: SP-20201Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Sarfez Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pancreatitis
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Pancreatitis in USA (unspecified route) (Sarfez Pharmaceuticals website, September 2023)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Pancreatitis in USA
- 08 Dec 2015 Preclinical trials in Pancreatitis in USA (unspecified route) prior to December 2015